Skip to main content
Erschienen in: Clinical & Experimental Metastasis 3/2019

11.04.2019 | Review

The extracellular matrix in tumor progression and metastasis

verfasst von: Johannes A. Eble, Stephan Niland

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

The extracellular matrix (ECM) constitutes the scaffold of tissues and organs. It is a complex network of extracellular proteins, proteoglycans and glycoproteins, which form supramolecular aggregates, such as fibrils and sheet-like networks. In addition to its biochemical composition, including the covalent intermolecular cross-linkages, the ECM is also characterized by its biophysical parameters, such as topography, molecular density, stiffness/rigidity and tension. Taking these biochemical and biophysical parameters into consideration, the ECM is very versatile and undergoes constant remodeling. This review focusses on this remodeling of the ECM under the influence of a primary solid tumor mass. Within this tumor stroma, not only the cancer cells but also the resident fibroblasts, which differentiate into cancer-associated fibroblasts (CAFs), modify the ECM. Growth factors and chemokines, which are tethered to and released from the ECM, as well as metabolic changes of the cells within the tumor bulk, add to the tumor-supporting tumor microenvironment. Metastasizing cancer cells from a primary tumor mass infiltrate into the ECM, which variably may facilitate cancer cell migration or act as barrier, which has to be proteolytically breached by the infiltrating tumor cell. The biochemical and biophysical properties therefore determine the rates and routes of metastatic dissemination. Moreover, primed by soluble factors of the primary tumor, the ECM of distant organs may be remodeled in a way to facilitate the engraftment of metastasizing cancer cells. Such premetastatic niches are responsible for the organotropic preference of certain cancer entities to colonize at certain sites in distant organs and to establish a metastasis. Translational application of our knowledge about the cancer-primed ECM is sparse with respect to therapeutic approaches, whereas tumor-induced ECM alterations such as increased tissue stiffness and desmoplasia, as well as breaching the basement membrane are hallmark of malignancy and diagnostically and histologically harnessed.
Literatur
27.
Zurück zum Zitat Cummings CF, Pedchenko V, Brown KL, Colon S, Rafi M, Jones-Paris C, Pokydeshava E, Liu M, Pastor-Pareja JC, Stothers C, Ero-Tolliver IA, McCall AS, Vanacore R, Bhave G, Santoro S, Blackwell TS, Zent R, Pozzi A, Hudson BG (2016) Extracellular chloride signals collagen IV network assembly during basement membrane formation. J Cell Biol 213(4):479–494. https://doi.org/10.1083/jcb.201510065 CrossRefPubMedPubMedCentral Cummings CF, Pedchenko V, Brown KL, Colon S, Rafi M, Jones-Paris C, Pokydeshava E, Liu M, Pastor-Pareja JC, Stothers C, Ero-Tolliver IA, McCall AS, Vanacore R, Bhave G, Santoro S, Blackwell TS, Zent R, Pozzi A, Hudson BG (2016) Extracellular chloride signals collagen IV network assembly during basement membrane formation. J Cell Biol 213(4):479–494. https://​doi.​org/​10.​1083/​jcb.​201510065 CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Vanacore RM, Friedman DB, Ham AJ, Sundaramoorthy M, Hudson BG (2005) Identification of S-hydroxylysyl-methionine as the covalent cross-link of the noncollagenous (NC1) hexamer of the α1α1α2 collagen IV network: a role for the post-translational modification of lysine 211 to hydroxylysine 211 in hexamer assembly. J Biol Chem 280(32):29300–29310. https://doi.org/10.1074/jbc.M502752200 CrossRefPubMed Vanacore RM, Friedman DB, Ham AJ, Sundaramoorthy M, Hudson BG (2005) Identification of S-hydroxylysyl-methionine as the covalent cross-link of the noncollagenous (NC1) hexamer of the α1α1α2 collagen IV network: a role for the post-translational modification of lysine 211 to hydroxylysine 211 in hexamer assembly. J Biol Chem 280(32):29300–29310. https://​doi.​org/​10.​1074/​jbc.​M502752200 CrossRefPubMed
30.
Zurück zum Zitat Shaw LM, Olsen BR (1991) FACIT collagens: diverse molecular bridges in extracellular matrices. Trends Biochem Sci 16(5):191–194CrossRefPubMed Shaw LM, Olsen BR (1991) FACIT collagens: diverse molecular bridges in extracellular matrices. Trends Biochem Sci 16(5):191–194CrossRefPubMed
34.
Zurück zum Zitat Li B, Cerione RA, Antonyak M (2011) Tissue transglutaminase and its role in human cancer progression. Adv Enzymol Relat Areas Mol Biol 78:247–293CrossRefPubMed Li B, Cerione RA, Antonyak M (2011) Tissue transglutaminase and its role in human cancer progression. Adv Enzymol Relat Areas Mol Biol 78:247–293CrossRefPubMed
47.
Zurück zum Zitat Hohenester E, Engel J (2002) Domain structure and organisation in extracellular matrix proteins. Matrix Biol 21(2):115–128CrossRefPubMed Hohenester E, Engel J (2002) Domain structure and organisation in extracellular matrix proteins. Matrix Biol 21(2):115–128CrossRefPubMed
56.
Zurück zum Zitat Chiquet-Ehrismann R, Hagios C, Matsumoto K (1994) The tenascin gene family. Perspect Dev Neurobiol 2(1):3–7PubMed Chiquet-Ehrismann R, Hagios C, Matsumoto K (1994) The tenascin gene family. Perspect Dev Neurobiol 2(1):3–7PubMed
59.
Zurück zum Zitat Naschberger E, Liebl A, Schellerer VS, Schutz M, Britzen-Laurent N, Kolbel P, Schaal U, Haep L, Regensburger D, Wittmann T, Klein-Hitpass L, Rau TT, Dietel B, Meniel VS, Clarke AR, Merkel S, Croner RS, Hohenberger W, Sturzl M (2016) Matricellular protein SPARCL1 regulates tumor microenvironment-dependent endothelial cell heterogeneity in colorectal carcinoma. J Clin Invest 126(11):4187–4204. https://doi.org/10.1172/JCI78260 CrossRefPubMedPubMedCentral Naschberger E, Liebl A, Schellerer VS, Schutz M, Britzen-Laurent N, Kolbel P, Schaal U, Haep L, Regensburger D, Wittmann T, Klein-Hitpass L, Rau TT, Dietel B, Meniel VS, Clarke AR, Merkel S, Croner RS, Hohenberger W, Sturzl M (2016) Matricellular protein SPARCL1 regulates tumor microenvironment-dependent endothelial cell heterogeneity in colorectal carcinoma. J Clin Invest 126(11):4187–4204. https://​doi.​org/​10.​1172/​JCI78260 CrossRefPubMedPubMedCentral
109.
Zurück zum Zitat Degen M, Brellier F, Schenk S, Driscoll R, Zaman K, Stupp R, Tornillo L, Terracciano L, Chiquet-Ehrismann R, Ruegg C, Seelentag W (2008) Tenascin-W, a new marker of cancer stroma, is elevated in sera of colon and breast cancer patients. Int J Cancer 122(11):2454–2461. https://doi.org/10.1002/ijc.23417 CrossRefPubMed Degen M, Brellier F, Schenk S, Driscoll R, Zaman K, Stupp R, Tornillo L, Terracciano L, Chiquet-Ehrismann R, Ruegg C, Seelentag W (2008) Tenascin-W, a new marker of cancer stroma, is elevated in sera of colon and breast cancer patients. Int J Cancer 122(11):2454–2461. https://​doi.​org/​10.​1002/​ijc.​23417 CrossRefPubMed
112.
Zurück zum Zitat Tsuruta D, Kobayashi H, Imanishi H, Sugawara K, Ishii M, Jones JC (2008) Laminin-332-integrin interaction: a target for cancer therapy? Curr Med Chem 15(20):1968–1975CrossRefPubMedPubMedCentral Tsuruta D, Kobayashi H, Imanishi H, Sugawara K, Ishii M, Jones JC (2008) Laminin-332-integrin interaction: a target for cancer therapy? Curr Med Chem 15(20):1968–1975CrossRefPubMedPubMedCentral
122.
Zurück zum Zitat Cavaco ACM, Rezaei M, Caliandro MF, Lima AM, Stehling M, Dhayat SA, Haier J, Brakebusch C, Eble JA (2018) The interaction between laminin-332 and α3β1 integrin determines differentiation and maintenance of CAFs, and supports invasion of pancreatic duct adenocarcinoma cells. Cancers (Basel) 11(1):14. https://doi.org/10.3390/cancers11010014 CrossRef Cavaco ACM, Rezaei M, Caliandro MF, Lima AM, Stehling M, Dhayat SA, Haier J, Brakebusch C, Eble JA (2018) The interaction between laminin-332 and α3β1 integrin determines differentiation and maintenance of CAFs, and supports invasion of pancreatic duct adenocarcinoma cells. Cancers (Basel) 11(1):14. https://​doi.​org/​10.​3390/​cancers11010014 CrossRef
137.
Zurück zum Zitat Yahyapour R, Motevaseli E, Rezaeyan A, Abdollahi H, Farhood B, Cheki M, Rezapoor S, Shabeeb D, Musa AE, Najafi M, Villa V (2018) Reduction-oxidation (redox) system in radiation-induced normal tissue injury: molecular mechanisms and implications in radiation therapeutics. Clin Transl Oncol 20(8):975–988. https://doi.org/10.1007/s12094-017-1828-6 CrossRefPubMed Yahyapour R, Motevaseli E, Rezaeyan A, Abdollahi H, Farhood B, Cheki M, Rezapoor S, Shabeeb D, Musa AE, Najafi M, Villa V (2018) Reduction-oxidation (redox) system in radiation-induced normal tissue injury: molecular mechanisms and implications in radiation therapeutics. Clin Transl Oncol 20(8):975–988. https://​doi.​org/​10.​1007/​s12094-017-1828-6 CrossRefPubMed
140.
Zurück zum Zitat Melincovici CS, Bosca AB, Susman S, Marginean M, Mihu C, Istrate M, Moldovan IM, Roman AL, Mihu CM (2018) Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis. Rom J Morphol Embryol 59(2):455–467PubMed Melincovici CS, Bosca AB, Susman S, Marginean M, Mihu C, Istrate M, Moldovan IM, Roman AL, Mihu CM (2018) Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis. Rom J Morphol Embryol 59(2):455–467PubMed
147.
153.
Zurück zum Zitat Reid SE, Kay EJ, Neilson LJ, Henze AT, Serneels J, McGhee EJ, Dhayade S, Nixon C, Mackey JB, Santi A, Swaminathan K, Athineos D, Papalazarou V, Patella F, Roman-Fernandez A, ElMaghloob Y, Hernandez-Fernaud JR, Adams RH, Ismail S, Bryant DM, Salmeron-Sanchez M, Machesky LM, Carlin LM, Blyth K, Mazzone M, Zanivan S (2017) Tumor matrix stiffness promotes metastatic cancer cell interaction with the endothelium. EMBO J 36(16):2373–2389. https://doi.org/10.15252/embj.201694912 CrossRefPubMedPubMedCentral Reid SE, Kay EJ, Neilson LJ, Henze AT, Serneels J, McGhee EJ, Dhayade S, Nixon C, Mackey JB, Santi A, Swaminathan K, Athineos D, Papalazarou V, Patella F, Roman-Fernandez A, ElMaghloob Y, Hernandez-Fernaud JR, Adams RH, Ismail S, Bryant DM, Salmeron-Sanchez M, Machesky LM, Carlin LM, Blyth K, Mazzone M, Zanivan S (2017) Tumor matrix stiffness promotes metastatic cancer cell interaction with the endothelium. EMBO J 36(16):2373–2389. https://​doi.​org/​10.​15252/​embj.​201694912 CrossRefPubMedPubMedCentral
157.
Zurück zum Zitat Seftor RE, Seftor EA, Kirschmann DA, Hendrix MJ (2002) Targeting the tumor microenvironment with chemically modified tetracyclines: inhibition of laminin 5 gamma2 chain promigratory fragments and vasculogenic mimicry. Mol Cancer Ther 1(13):1173–1179PubMed Seftor RE, Seftor EA, Kirschmann DA, Hendrix MJ (2002) Targeting the tumor microenvironment with chemically modified tetracyclines: inhibition of laminin 5 gamma2 chain promigratory fragments and vasculogenic mimicry. Mol Cancer Ther 1(13):1173–1179PubMed
181.
Zurück zum Zitat Angst BD, Marcozzi C, Magee AI (2001) The cadherin superfamily. J Cell Sci 114(Pt 4):625–626PubMed Angst BD, Marcozzi C, Magee AI (2001) The cadherin superfamily. J Cell Sci 114(Pt 4):625–626PubMed
203.
Zurück zum Zitat Parvanescu V, Georgescu M, Georgescu I, Surlin V, Patrascu S, Picleanu AM, Georgescu E (2015) The role of matrix metalloproteinase-9 (MMP-9) as a prognostic factor in epithelial and lymphatic neoplasia. Chirurgia (Bucur) 110(6):506–510 Parvanescu V, Georgescu M, Georgescu I, Surlin V, Patrascu S, Picleanu AM, Georgescu E (2015) The role of matrix metalloproteinase-9 (MMP-9) as a prognostic factor in epithelial and lymphatic neoplasia. Chirurgia (Bucur) 110(6):506–510
204.
Zurück zum Zitat Tam EM, Moore TR, Butler GS, Overall CM (2004) Characterization of the distinct collagen binding, helicase and cleavage mechanisms of matrix metalloproteinase 2 and 14 (gelatinase A and MT1-MMP): the differential roles of the MMP hemopexin c domains and the MMP-2 fibronectin type II modules in collagen triple helicase activities. J Biol Chem 279(41):43336–43344. https://doi.org/10.1074/jbc.M407186200 CrossRefPubMed Tam EM, Moore TR, Butler GS, Overall CM (2004) Characterization of the distinct collagen binding, helicase and cleavage mechanisms of matrix metalloproteinase 2 and 14 (gelatinase A and MT1-MMP): the differential roles of the MMP hemopexin c domains and the MMP-2 fibronectin type II modules in collagen triple helicase activities. J Biol Chem 279(41):43336–43344. https://​doi.​org/​10.​1074/​jbc.​M407186200 CrossRefPubMed
206.
Zurück zum Zitat Overall CM (2001) Matrix metalloproteinase substrate binding domains, modules and exosites. Overview and experimental strategies. Methods Mol Biol 151:79–120PubMed Overall CM (2001) Matrix metalloproteinase substrate binding domains, modules and exosites. Overview and experimental strategies. Methods Mol Biol 151:79–120PubMed
209.
Zurück zum Zitat Saad S, Gottlieb DJ, Bradstock KF, Overall CM, Bendall LJ (2002) Cancer cell-associated fibronectin induces release of matrix metalloproteinase-2 from normal fibroblasts. Cancer Res 62(1):283–289PubMed Saad S, Gottlieb DJ, Bradstock KF, Overall CM, Bendall LJ (2002) Cancer cell-associated fibronectin induces release of matrix metalloproteinase-2 from normal fibroblasts. Cancer Res 62(1):283–289PubMed
213.
Zurück zum Zitat Revach OY, Geiger B (2014) The interplay between the proteolytic, invasive, and adhesive domains of invadopodia and their roles in cancer invasion. Cell Adhes Migr 8(3):215–225CrossRef Revach OY, Geiger B (2014) The interplay between the proteolytic, invasive, and adhesive domains of invadopodia and their roles in cancer invasion. Cell Adhes Migr 8(3):215–225CrossRef
231.
Zurück zum Zitat Hornebeck W, Maquart FX (2003) Proteolyzed matrix as a template for the regulation of tumor progression. Biomed Pharmacother 57(5–6):223–230CrossRefPubMed Hornebeck W, Maquart FX (2003) Proteolyzed matrix as a template for the regulation of tumor progression. Biomed Pharmacother 57(5–6):223–230CrossRefPubMed
236.
Zurück zum Zitat Hope C, Emmerich PB, Papadas A, Pagenkopf A, Matkowskyj KA, Van De Hey DR, Payne SN, Clipson L, Callander NS, Hematti P, Miyamoto S, Johnson MG, Deming DA, Asimakopoulos F (2017) Versican-derived matrikines regulate Batf3-dendritic cell differentiation and promote T cell infiltration in colorectal cancer. J Immunol 199(5):1933–1941. https://doi.org/10.4049/jimmunol.1700529 CrossRefPubMed Hope C, Emmerich PB, Papadas A, Pagenkopf A, Matkowskyj KA, Van De Hey DR, Payne SN, Clipson L, Callander NS, Hematti P, Miyamoto S, Johnson MG, Deming DA, Asimakopoulos F (2017) Versican-derived matrikines regulate Batf3-dendritic cell differentiation and promote T cell infiltration in colorectal cancer. J Immunol 199(5):1933–1941. https://​doi.​org/​10.​4049/​jimmunol.​1700529 CrossRefPubMed
273.
Zurück zum Zitat Arnold M, Hirschfeld-Warneken VC, Lohmuller T, Heil P, Blummel J, Cavalcanti-Adam EA, Lopez-Garcia M, Walther P, Kessler H, Geiger B, Spatz JP (2008) Induction of cell polarization and migration by a gradient of nanoscale variations in adhesive ligand spacing. Nano Lett 8(7):2063–2069. https://doi.org/10.1021/nl801483w CrossRefPubMed Arnold M, Hirschfeld-Warneken VC, Lohmuller T, Heil P, Blummel J, Cavalcanti-Adam EA, Lopez-Garcia M, Walther P, Kessler H, Geiger B, Spatz JP (2008) Induction of cell polarization and migration by a gradient of nanoscale variations in adhesive ligand spacing. Nano Lett 8(7):2063–2069. https://​doi.​org/​10.​1021/​nl801483w CrossRefPubMed
290.
Zurück zum Zitat Gaggioli C, Hooper S, Hidalgo-Carcedo C, Grosse R, Marshall JF, Harrington K, Sahai E (2007) Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat Cell Biol 9(12):1392–1400. https://doi.org/10.1038/ncb1658 CrossRefPubMed Gaggioli C, Hooper S, Hidalgo-Carcedo C, Grosse R, Marshall JF, Harrington K, Sahai E (2007) Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat Cell Biol 9(12):1392–1400. https://​doi.​org/​10.​1038/​ncb1658 CrossRefPubMed
291.
292.
Zurück zum Zitat Camerer E (2004) Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 104:397–401CrossRefPubMed Camerer E (2004) Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 104:397–401CrossRefPubMed
296.
Zurück zum Zitat Peinado H, Zhang H, Matei IR, Costa-Silva B, Hoshino A, Rodrigues G, Psaila B, Kaplan RN, Bromberg JF, Kang Y, Bissell MJ, Cox TR, Giaccia AJ, Erler JT, Hiratsuka S, Ghajar CM, Lyden D (2017) Pre-metastatic niches: organ-specific homes for metastases. Nat Rev Cancer 17(5):302–317. https://doi.org/10.1038/nrc.2017.6 CrossRefPubMed Peinado H, Zhang H, Matei IR, Costa-Silva B, Hoshino A, Rodrigues G, Psaila B, Kaplan RN, Bromberg JF, Kang Y, Bissell MJ, Cox TR, Giaccia AJ, Erler JT, Hiratsuka S, Ghajar CM, Lyden D (2017) Pre-metastatic niches: organ-specific homes for metastases. Nat Rev Cancer 17(5):302–317. https://​doi.​org/​10.​1038/​nrc.​2017.​6 CrossRefPubMed
298.
Zurück zum Zitat Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di Giannatale A, Ceder S, Singh S, Williams C, Soplop N, Uryu K, Pharmer L, King T, Bojmar L, Davies AE, Ararso Y, Zhang T, Zhang H, Hernandez J, Weiss JM, Dumont-Cole VD, Kramer K, Wexler LH, Narendran A, Schwartz GK, Healey JH, Sandstrom P, Labori KJ, Kure EH, Grandgenett PM, Hollingsworth MA, de Sousa M, Kaur S, Jain M, Mallya K, Batra SK, Jarnagin WR, Brady MS, Fodstad O, Muller V, Pantel K, Minn AJ, Bissell MJ, Garcia BA, Kang Y, Rajasekhar VK, Ghajar CM, Matei I, Peinado H, Bromberg J, Lyden D (2015) Tumour exosome integrins determine organotropic metastasis. Nature 527(7578):329–335. https://doi.org/10.1038/nature15756 CrossRefPubMedPubMedCentral Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di Giannatale A, Ceder S, Singh S, Williams C, Soplop N, Uryu K, Pharmer L, King T, Bojmar L, Davies AE, Ararso Y, Zhang T, Zhang H, Hernandez J, Weiss JM, Dumont-Cole VD, Kramer K, Wexler LH, Narendran A, Schwartz GK, Healey JH, Sandstrom P, Labori KJ, Kure EH, Grandgenett PM, Hollingsworth MA, de Sousa M, Kaur S, Jain M, Mallya K, Batra SK, Jarnagin WR, Brady MS, Fodstad O, Muller V, Pantel K, Minn AJ, Bissell MJ, Garcia BA, Kang Y, Rajasekhar VK, Ghajar CM, Matei I, Peinado H, Bromberg J, Lyden D (2015) Tumour exosome integrins determine organotropic metastasis. Nature 527(7578):329–335. https://​doi.​org/​10.​1038/​nature15756 CrossRefPubMedPubMedCentral
315.
Zurück zum Zitat Leprini A, Querze G, Zardi L (1994) Tenascin isoforms: possible targets for diagnosis and therapy of cancer and mechanisms regulating their expression. Perspect Dev Neurobiol 2(1):117–123PubMed Leprini A, Querze G, Zardi L (1994) Tenascin isoforms: possible targets for diagnosis and therapy of cancer and mechanisms regulating their expression. Perspect Dev Neurobiol 2(1):117–123PubMed
316.
Zurück zum Zitat Nicolo G, Salvi S, Oliveri G, Borsi L, Castellani P, Zardi L (1990) Expression of tenascin and of the ED-B containing oncofetal fibronectin isoform in human cancer. Cell Differ Dev 32(3):401–408CrossRefPubMed Nicolo G, Salvi S, Oliveri G, Borsi L, Castellani P, Zardi L (1990) Expression of tenascin and of the ED-B containing oncofetal fibronectin isoform in human cancer. Cell Differ Dev 32(3):401–408CrossRefPubMed
322.
Zurück zum Zitat Rizvi NA, Humphrey JS, Ness EA, Johnson MD, Gupta E, Williams K, Daly DJ, Sonnichsen D, Conway D, Marshall J, Hurwitz H (2004) A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer. Clin Cancer Res 10(6):1963–1970CrossRefPubMed Rizvi NA, Humphrey JS, Ness EA, Johnson MD, Gupta E, Williams K, Daly DJ, Sonnichsen D, Conway D, Marshall J, Hurwitz H (2004) A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer. Clin Cancer Res 10(6):1963–1970CrossRefPubMed
323.
Zurück zum Zitat Leighl NB, Paz-Ares L, Douillard JY, Peschel C, Arnold A, Depierre A, Santoro A, Betticher DC, Gatzemeier U, Jassem J, Crawford J, Tu D, Bezjak A, Humphrey JS, Voi M, Galbraith S, Hann K, Seymour L, Shepherd FA (2005) Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. J Clin Oncol 23(12):2831–2839. https://doi.org/10.1200/JCO.2005.04.044 CrossRefPubMed Leighl NB, Paz-Ares L, Douillard JY, Peschel C, Arnold A, Depierre A, Santoro A, Betticher DC, Gatzemeier U, Jassem J, Crawford J, Tu D, Bezjak A, Humphrey JS, Voi M, Galbraith S, Hann K, Seymour L, Shepherd FA (2005) Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. J Clin Oncol 23(12):2831–2839. https://​doi.​org/​10.​1200/​JCO.​2005.​04.​044 CrossRefPubMed
324.
Zurück zum Zitat Hirte H, Vergote IB, Jeffrey JR, Grimshaw RN, Coppieters S, Schwartz B, Tu D, Sadura A, Brundage M, Seymour L (2006) A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study. Gynecol Oncol 102(2):300–308. https://doi.org/10.1016/j.ygyno.2005.12.020 CrossRefPubMed Hirte H, Vergote IB, Jeffrey JR, Grimshaw RN, Coppieters S, Schwartz B, Tu D, Sadura A, Brundage M, Seymour L (2006) A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study. Gynecol Oncol 102(2):300–308. https://​doi.​org/​10.​1016/​j.​ygyno.​2005.​12.​020 CrossRefPubMed
325.
Zurück zum Zitat Hande KR, Collier M, Paradiso L, Stuart-Smith J, Dixon M, Clendeninn N, Yeun G, Alberti D, Binger K, Wilding G (2004) Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor. Clin Cancer Res 10(3):909–915CrossRefPubMed Hande KR, Collier M, Paradiso L, Stuart-Smith J, Dixon M, Clendeninn N, Yeun G, Alberti D, Binger K, Wilding G (2004) Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor. Clin Cancer Res 10(3):909–915CrossRefPubMed
327.
Zurück zum Zitat Paemen L, Martens E, Masure S, Opdenakker G (1995) Monoclonal antibodies specific for natural human neutrophil gelatinase B used for affinity purification, quantitation by two-site ELISA and inhibition of enzymatic activity. Eur J Biochem 234(3):759–765CrossRefPubMed Paemen L, Martens E, Masure S, Opdenakker G (1995) Monoclonal antibodies specific for natural human neutrophil gelatinase B used for affinity purification, quantitation by two-site ELISA and inhibition of enzymatic activity. Eur J Biochem 234(3):759–765CrossRefPubMed
328.
Zurück zum Zitat Martens E, Leyssen A, Van Aelst I, Fiten P, Piccard H, Hu J, Descamps FJ, Van den Steen PE, Proost P, Van Damme J, Liuzzi GM, Riccio P, Polverini E, Opdenakker G (2007) A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains. Biochim Biophys Acta 1770(2):178–186. https://doi.org/10.1016/j.bbagen.2006.10.012 CrossRefPubMed Martens E, Leyssen A, Van Aelst I, Fiten P, Piccard H, Hu J, Descamps FJ, Van den Steen PE, Proost P, Van Damme J, Liuzzi GM, Riccio P, Polverini E, Opdenakker G (2007) A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains. Biochim Biophys Acta 1770(2):178–186. https://​doi.​org/​10.​1016/​j.​bbagen.​2006.​10.​012 CrossRefPubMed
329.
Zurück zum Zitat Devy L, Huang L, Naa L, Yanamandra N, Pieters H, Frans N, Chang E, Tao Q, Vanhove M, Lejeune A, van Gool R, Sexton DJ, Kuang G, Rank D, Hogan S, Pazmany C, Ma YL, Schoonbroodt S, Nixon AE, Ladner RC, Hoet R, Henderikx P, Tenhoor C, Rabbani SA, Valentino ML, Wood CR, Dransfield DT (2009) Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res 69(4):1517–1526. https://doi.org/10.1158/0008-5472.CAN-08-3255 CrossRefPubMed Devy L, Huang L, Naa L, Yanamandra N, Pieters H, Frans N, Chang E, Tao Q, Vanhove M, Lejeune A, van Gool R, Sexton DJ, Kuang G, Rank D, Hogan S, Pazmany C, Ma YL, Schoonbroodt S, Nixon AE, Ladner RC, Hoet R, Henderikx P, Tenhoor C, Rabbani SA, Valentino ML, Wood CR, Dransfield DT (2009) Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res 69(4):1517–1526. https://​doi.​org/​10.​1158/​0008-5472.​CAN-08-3255 CrossRefPubMed
334.
Zurück zum Zitat Chan N, Willis A, Kornhauser N, Ward MM, Lee SB, Nackos E, Seo BR, Chuang E, Cigler T, Moore A, Donovan D, Vallee Cobham M, Fitzpatrick V, Schneider S, Wiener A, Guillaume-Abraham J, Aljom E, Zelkowitz R, Warren JD, Lane ME, Fischbach C, Mittal V, Vahdat L (2017) Influencing the tumor microenvironment: a phase II study of copper depletion using tetrathiomolybdate in patients with breast cancer at high risk for recurrence and in preclinical models of lung metastases. Clin Cancer Res 23(3):666–676. https://doi.org/10.1158/1078-0432.CCR-16-1326 CrossRefPubMed Chan N, Willis A, Kornhauser N, Ward MM, Lee SB, Nackos E, Seo BR, Chuang E, Cigler T, Moore A, Donovan D, Vallee Cobham M, Fitzpatrick V, Schneider S, Wiener A, Guillaume-Abraham J, Aljom E, Zelkowitz R, Warren JD, Lane ME, Fischbach C, Mittal V, Vahdat L (2017) Influencing the tumor microenvironment: a phase II study of copper depletion using tetrathiomolybdate in patients with breast cancer at high risk for recurrence and in preclinical models of lung metastases. Clin Cancer Res 23(3):666–676. https://​doi.​org/​10.​1158/​1078-0432.​CCR-16-1326 CrossRefPubMed
335.
336.
337.
Zurück zum Zitat Barry-Hamilton V, Spangler R, Marshall D, McCauley S, Rodriguez HM, Oyasu M, Mikels A, Vaysberg M, Ghermazien H, Wai C, Garcia CA, Velayo AC, Jorgensen B, Biermann D, Tsai D, Green J, Zaffryar-Eilot S, Holzer A, Ogg S, Thai D, Neufeld G, Van Vlasselaer P, Smith V (2010) Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med 16(9):1009–1017. https://doi.org/10.1038/nm.2208 CrossRefPubMed Barry-Hamilton V, Spangler R, Marshall D, McCauley S, Rodriguez HM, Oyasu M, Mikels A, Vaysberg M, Ghermazien H, Wai C, Garcia CA, Velayo AC, Jorgensen B, Biermann D, Tsai D, Green J, Zaffryar-Eilot S, Holzer A, Ogg S, Thai D, Neufeld G, Van Vlasselaer P, Smith V (2010) Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med 16(9):1009–1017. https://​doi.​org/​10.​1038/​nm.​2208 CrossRefPubMed
339.
Zurück zum Zitat Rasmussen HS, McCann PP (1997) Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther 75(1):69–75CrossRefPubMed Rasmussen HS, McCann PP (1997) Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther 75(1):69–75CrossRefPubMed
341.
Zurück zum Zitat Rao BG (2005) Recent developments in the design of specific matrix metalloproteinase inhibitors aided by structural and computational studies. Curr Pharm Des 11(3):295–322CrossRefPubMed Rao BG (2005) Recent developments in the design of specific matrix metalloproteinase inhibitors aided by structural and computational studies. Curr Pharm Des 11(3):295–322CrossRefPubMed
358.
Zurück zum Zitat Bax DV, Mahalingam Y, Cain S, Mellody K, Freeman L, Younger K, Shuttleworth CA, Humphries MJ, Couchman JR, Kielty CM (2007) Cell adhesion to fibrillin-1: identification of an Arg-Gly-Asp-dependent synergy region and a heparin-binding site that regulates focal adhesion formation. J Cell Sci 120(Pt 8):1383–1392. https://doi.org/10.1242/jcs.003954 CrossRefPubMed Bax DV, Mahalingam Y, Cain S, Mellody K, Freeman L, Younger K, Shuttleworth CA, Humphries MJ, Couchman JR, Kielty CM (2007) Cell adhesion to fibrillin-1: identification of an Arg-Gly-Asp-dependent synergy region and a heparin-binding site that regulates focal adhesion formation. J Cell Sci 120(Pt 8):1383–1392. https://​doi.​org/​10.​1242/​jcs.​003954 CrossRefPubMed
365.
Zurück zum Zitat Mercuri FA, Maciewicz RA, Tart J, Last K, Fosang AJ (2000) Mutations in the interglobular domain of aggrecan alter matrix metalloproteinase and aggrecanase cleavage patterns Evidence that matrix metalloproteinase cleavage interferes with aggrecanase activity. J Biol Chem 275(42):33038–33045CrossRefPubMed Mercuri FA, Maciewicz RA, Tart J, Last K, Fosang AJ (2000) Mutations in the interglobular domain of aggrecan alter matrix metalloproteinase and aggrecanase cleavage patterns Evidence that matrix metalloproteinase cleavage interferes with aggrecanase activity. J Biol Chem 275(42):33038–33045CrossRefPubMed
368.
Zurück zum Zitat Li H, Leung TC, Hoffman S, Balsamo J, Lilien J (2000) Coordinate regulation of cadherin and integrin function by the chondroitin sulfate proteoglycan neurocan. J Cell Biol 149(6):1275–1288CrossRefPubMedPubMedCentral Li H, Leung TC, Hoffman S, Balsamo J, Lilien J (2000) Coordinate regulation of cadherin and integrin function by the chondroitin sulfate proteoglycan neurocan. J Cell Biol 149(6):1275–1288CrossRefPubMedPubMedCentral
372.
Zurück zum Zitat Iozzo RV, Moscatello DK, McQuillan DJ, Eichstetter I (1999) Decorin is a biological ligand for the epidermal growth factor receptor. J Biol Chem 274(8):4489–4492CrossRefPubMed Iozzo RV, Moscatello DK, McQuillan DJ, Eichstetter I (1999) Decorin is a biological ligand for the epidermal growth factor receptor. J Biol Chem 274(8):4489–4492CrossRefPubMed
376.
Zurück zum Zitat Hausser H, Wedekind P, Sperber T, Peters R, Hasilik A, Kresse H (1996) Isolation and cellular localization of the decorin endocytosis receptor. Eur J Cell Biol 71(4):325–331PubMed Hausser H, Wedekind P, Sperber T, Peters R, Hasilik A, Kresse H (1996) Isolation and cellular localization of the decorin endocytosis receptor. Eur J Cell Biol 71(4):325–331PubMed
379.
Zurück zum Zitat Eble JA, Wucherpfennig KW, Gauthier L, Dersch P, Krukonis E, Isberg RR, Hemler ME (1998) Recombinant soluble human α3β1 integrin: purification, processing, regulation, and specific binding to laminin-5 and invasin in a mutually exclusive manner. Biochemistry 37(31):10945–10955. https://doi.org/10.1021/bi980175+ CrossRefPubMed Eble JA, Wucherpfennig KW, Gauthier L, Dersch P, Krukonis E, Isberg RR, Hemler ME (1998) Recombinant soluble human α3β1 integrin: purification, processing, regulation, and specific binding to laminin-5 and invasin in a mutually exclusive manner. Biochemistry 37(31):10945–10955. https://​doi.​org/​10.​1021/​bi980175+ CrossRefPubMed
385.
Zurück zum Zitat Babic AM, Chen CC, Lau LF (1999) Fisp12/mouse connective tissue growth factor mediates endothelial cell adhesion and migration through integrin αvβ3, promotes endothelial cell survival, and induces angiogenesis in vivo. Mol Cell Biol 19(4):2958–2966CrossRefPubMedPubMedCentral Babic AM, Chen CC, Lau LF (1999) Fisp12/mouse connective tissue growth factor mediates endothelial cell adhesion and migration through integrin αvβ3, promotes endothelial cell survival, and induces angiogenesis in vivo. Mol Cell Biol 19(4):2958–2966CrossRefPubMedPubMedCentral
386.
Zurück zum Zitat Scherberich A, Tucker RP, Degen M, Brown-Luedi M, Andres AC, Chiquet-Ehrismann R (2005) Tenascin-W is found in malignant mammary tumors, promotes α8 integrin-dependent motility and requires p38MAPK activity for BMP-2 and TNF-α induced expression in vitro. Oncogene 24(9):1525–1532. https://doi.org/10.1038/sj.onc.1208342 CrossRefPubMed Scherberich A, Tucker RP, Degen M, Brown-Luedi M, Andres AC, Chiquet-Ehrismann R (2005) Tenascin-W is found in malignant mammary tumors, promotes α8 integrin-dependent motility and requires p38MAPK activity for BMP-2 and TNF-α induced expression in vitro. Oncogene 24(9):1525–1532. https://​doi.​org/​10.​1038/​sj.​onc.​1208342 CrossRefPubMed
388.
Zurück zum Zitat Gillan L, Matei D, Fishman DA, Gerbin CS, Karlan BY, Chang DD (2002) Periostin secreted by epithelial ovarian carcinoma is a ligand for αVβ3 and αVβ5 integrins and promotes cell motility. Cancer Res 62(18):5358–5364PubMed Gillan L, Matei D, Fishman DA, Gerbin CS, Karlan BY, Chang DD (2002) Periostin secreted by epithelial ovarian carcinoma is a ligand for αVβ3 and αVβ5 integrins and promotes cell motility. Cancer Res 62(18):5358–5364PubMed
394.
Zurück zum Zitat Furger KA, Allan AL, Wilson SM, Hota C, Vantyghem SA, Postenka CO, Al-Katib W, Chambers AF, Tuck AB (2003) Β3 integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin. Mol Cancer Res 1(11):810–819PubMed Furger KA, Allan AL, Wilson SM, Hota C, Vantyghem SA, Postenka CO, Al-Katib W, Chambers AF, Tuck AB (2003) Β3 integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin. Mol Cancer Res 1(11):810–819PubMed
397.
Zurück zum Zitat Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, Li Y, Robles AI, Chen Y, Ma ZC, Wu ZQ, Ye SL, Liu YK, Tang ZY, Wang XW (2003) Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 9(4):416–423. https://doi.org/10.1038/nm843 CrossRefPubMed Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, Li Y, Robles AI, Chen Y, Ma ZC, Wu ZQ, Ye SL, Liu YK, Tang ZY, Wang XW (2003) Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 9(4):416–423. https://​doi.​org/​10.​1038/​nm843 CrossRefPubMed
Metadaten
Titel
The extracellular matrix in tumor progression and metastasis
verfasst von
Johannes A. Eble
Stephan Niland
Publikationsdatum
11.04.2019
Verlag
Springer Netherlands
Erschienen in
Clinical & Experimental Metastasis / Ausgabe 3/2019
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-019-09966-1

Weitere Artikel der Ausgabe 3/2019

Clinical & Experimental Metastasis 3/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.